Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension Trial - PubMed
4 days ago
- #mirikizumab
- #Crohn's disease
- #long-term efficacy
- Mirikizumab, an anti-IL-23p19 monoclonal antibody, showed efficacy and safety in Crohn's disease (CD) patients up to week 52 in the VIVID-1 trial.
- The VIVID-2 open-label extension study evaluated mirikizumab's long-term effects over two years in 465 patients (safety population), with 430 meeting efficacy criteria.
- At week 104, 60.5% (mNRI) and 67.1% (OC) of patients achieved endoscopic response, while 37.9%/41.7% achieved endoscopic remission, and 73.4%/80.9% achieved CDAI remission.
- Among week 52 endoscopic responders, high proportions maintained response (81.8%/87.6%), remission (72.5%/78.6%), and CDAI remission (86.9%/92.9%) at week 104.
- Week 52 non-responders showed improvement, with 30.9%/36.1% achieving endoscopic response and 33.3%/35.4% gaining remission by week 104 after reinduction.
- Safety profile remained consistent, with 64.7% experiencing treatment-emergent AEs and 7.7% having serious AEs during the second year.